Find disease awareness content and relevant supporting materials
MLHW (Japan) approves Keytruda + chemotherapy to treat triple negative breast cancer
Merck Inc., announced that Keytruda Merck’s anti-PD-1 therapy, received four new approvals from Japan’s Ministry of Health, Labor and Welfare (MHLW) including Keytruda in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for patients with hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative breast cancer at high risk of recurrence, based on data from the KEYNOTE-522 trial
NICE (UK) recommends Trodelvy to treat triple negative breast cancer.
NICE (National Institute for Health and Care Excellence (UK)recommended Trodelvy (also called sacituzumab govitecan and made by Gilead Sciences) for treating locally advanced or metastatic triple negative breast cancer which cannot be removed surgically.
A randomised phase II trial of [18F]fluorothymidine and the standard tracer [18F]Fluorodeoxyglucose in the assessment of systemic therapy response in triple negative breast cancer and their utility compared to conventional MRI imaging response, early ADC
Part A: To confirm repeatability of Positron Emission Tomography (PET) scan SUV measurement before chemotherapy in triple negative breast cancer...
A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer
The primary objective is to determine clinical benefit rate in patients with AR+ triple-negative breast cancer (TNBC).
Health Canada approves Trodelvy for locally advanced or metastatic triple-negative breast cancer.
Gilead Sciences, Inc. announced that Health Canada has approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior therapies, at least one of them for metastatic disease.
FDA approves Trodelvy, the first treatment for metastatic triple-negative breast cancer shown to improve progression-free survival and overall survival.- Gilead Sciences
Gilead Sciences, Inc. announced that the FDA has granted full approval to Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.